Influence of time of injection of recombinant porcine somatotropin (rpST) relative to time of feeding on growth performance, hormone and metabolite status, and muscle RNA, DNA, and protein in pigs.
Thirty-six barrows were used in a 2 X 3 factorial treatment array to determine the effects of time of injection (0800 [AM] or 1800 [PM]) of recombinant porcine somatotropin (rpST) (0, 50, or 100 micrograms.kg BW.d-1 adjusted weekly) relative to time of feeding on growth performance, carcass composition, serum hormones and metabolites, and muscle RNA, DNA, and protein. Pigs were fed at 85% of ad libitum and allowed access to feed between 0800 and 1200. Treatments were initiated at 38 kg and continued until each pig consumed an average of 7.5 Mcal of DE/d. There was no significant effect of injection time for any measure of growth performance or composition of gain even though rpST treatment improved most criteria evaluated. Treatment with rpST increased ADG by 30%, improved feed:gain by 23%, reduced lipid accretion by 46%, increased protein accretion by 69%, and increased loin eye area (LEA) by 26%. Time of injection also had no effect on serum hormones or metabolites, except for nonesterified fatty acids (NEFA), which were 20% higher in the AM-injected animals. Treatment with rpST increased (P less than .05) RNA concentration (21%) and RNA/DNA (17%) in longissimus dorsi (LD) muscle. In semimembranosus (SM) muscle, however, rpST administration resulted in an increased (P less than .05) DNA concentration (10%) and a decreased DM content (4%). These results suggest that rpST influences growth differently in these two muscles. We conclude that time of rpST administration (AM vs PM) has no effect on its metabolic properties and, therefore, no effect on growth performance in the pig.
Evock
C M
CM
U.S. Department of Agriculture, Beltsville, MD 20705.
Caperna
T J
TJ
Steele
N C
NC
McMurtry
J P
JP
Rosebrough
R W
RW
D000273:Adipose Tissue / Q000187:drug effects / Q000254:growth & development; D000818:Animals; D001823:Body Composition / Q000187:drug effects*; D004247:DNA / Q000032:analysis; D004305:Dose-Response Relationship, Drug; D004435:Eating; D002149:Energy Intake; D005230:Fatty Acids, Nonesterified / Q000097:blood; D013006:Growth Hormone / Q000008:administration & dosage / Q000494:pharmacology*; D006728:Hormones / Q000097:blood; D007273:Injections, Intramuscular / Q000662:veterinary; D008297:Male; D008460:Meat / Q000592:standards; D024510:Muscle Development; D009124:Muscle Proteins / Q000032:analysis; D009132:Muscles / Q000737:chemistry / Q000187:drug effects*; D012313:RNA / Q000032:analysis; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D013552:Swine / Q000254:growth & development* / Q000378:metabolism; D013997:Time Factors; D015430:Weight Gain / Q000187:drug effects
D005230:Fatty Acids, Nonesterified; D006728:Hormones; D009124:Muscle Proteins; D011994:Recombinant Proteins; D012313:RNA; D013006:Growth Hormone; D004247:DNA